aim
studi
assess
infecti
etiolog
patient
hospit
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
concomit
pneumonia
method
patient
admit
medic
ward
acut
hospit
recruit
prospect
may
april
sputum
cultur
blood
cultur
pair
serolog
nasopharyng
aspir
npa
viral
cultur
polymeras
chain
reaction
pcr
studi
perform
spirometri
assess
stabl
phase
month
posthospit
discharg
result
seventi
eight
subject
admit
aecopd
concomit
pneumonia
mean
sd
age
year
fev
predict
normal
overal
infecti
etiolog
could
establish
subject
among
subject
sputum
collect
posit
bacteri
cultur
commonest
bacteria
identifi
streptococcu
pneumonia
pseudomona
aeruginosa
haemophilu
influenza
among
subject
npa
collect
posit
viral
cultur
pcr
result
respect
commonest
virus
identifi
npa
pcr
influenza
subject
rhinoviru
pair
serolog
posit
patient
high
dose
inhal
corticosteroid
ic
mcg
beclomethasoneequivalentday
higher
rate
posit
sputum
bacteri
cultur
lowmedium
dose
ic
vs
p
z
v
l
b
l
e
w
w
w
c
e
n
c
e
r
e
c
c
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
r
e
respiratori
medicin
conclus
infecti
etiolog
could
establish
half
patient
hospit
aecopd
concomit
pneumonia
major
identifi
caus
bacteri
patient
high
dose
ic
might
impair
airway
defens
reflect
higher
rate
posit
sputum
cultur
pneumonia
major
caus
morbid
mortal
worldwid
us
pneumonia
common
caus
death
lead
caus
death
among
infecti
diseas
hong
kong
pneumonia
copd
lead
caus
death
mortal
rate
per
popul
respect
observ
studi
us
report
patient
communityacquir
pneumonia
cap
diagnosi
copd
significantli
higher
mortal
noncopd
patient
recent
use
inhal
corticosteroid
ic
associ
excess
risk
pneumonia
hospit
follow
death
within
day
among
elderli
patient
copd
studi
etiolog
cap
focu
copd
patient
addit
studi
infecti
etiolog
pneumonia
conduct
intens
care
unit
icu
set
specif
copd
hand
mani
studi
infecti
etiolog
relat
aecopd
exclud
patient
pneumonia
consid
pure
aecopd
group
previous
conduct
retrospect
studi
sputum
bacteriolog
patient
aecopd
concomit
pneumonia
caus
role
virus
explor
current
limit
data
etiolog
agent
patient
aecopd
concomit
pneumonia
aim
studi
assess
prospect
bacteri
viral
etiolog
patient
hospit
aecopd
concomit
pneumonia
addit
associ
identif
microorgan
aecopd
use
ic
clinic
outcom
includ
mortal
need
noninvas
posit
pressur
ventil
nppv
assess
patient
admit
princ
wale
hospit
aecopd
concomit
pneumonia
may
april
recruit
studi
aecopd
defin
patient
background
copd
present
least
two
follow
major
symptom
increas
dyspnea
increas
sputum
purul
increas
sputum
volum
one
major
one
minor
symptom
nasal
dischargecongest
wheez
sore
throat
cough
least
two
consecut
day
chest
radiograph
cxr
assess
investig
respiratori
physician
pneumonia
defin
radiograph
evid
chest
infect
new
infiltr
consolid
cxr
inform
written
consent
obtain
subject
studi
approv
research
ethic
committe
chines
univers
hong
kong
demograph
data
length
hospit
stay
patient
aecopd
record
comorbid
condit
note
score
charlson
index
score
charlson
index
rang
higher
score
indic
number
sever
coexist
ill
use
nppv
invas
mechan
ventil
icu
admiss
record
expector
sputum
collect
steril
contain
process
cultur
accord
standard
procedur
describ
previou
studi
npa
obtain
cathet
aspir
posterior
nasal
pharyng
space
via
nostril
patient
sit
posit
npa
viral
cultur
perform
describ
previou
studi
viral
pcr
assess
npa
group
nest
multiplex
pcr
assay
target
respiratori
virus
three
bacteria
appli
describ
previou
studi
virus
bacteria
includ
influenza
influenza
b
parainfluenza
type
respiratori
syncyti
virus
rsv
b
rhinoviru
enteroviru
coronavirus
sar
metapneumoviru
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
adenoviru
pair
serum
sampl
serolog
obtain
admiss
day
later
presenc
antibodi
specif
influenza
b
parainfluenza
rsv
adenoviru
pneumonia
chlamydia
psittaci
detect
complement
fixat
test
seroconvers
rise
antibodi
titr
regard
evid
current
infect
blood
cultur
use
bactalert
microbi
detect
system
spirometri
preand
postbronchodil
perform
month
postdischarg
stabl
copd
accord
american
thorac
societi
standard
use
vitalograph
buckingham
uk
spiromet
updat
predict
spirometri
valu
hong
kong
chines
adopt
patient
contact
phone
medic
record
review
month
later
check
death
readmiss
data
analyz
statist
packag
social
scienc
spss
statist
softwar
window
version
spss
inc
il
usa
associ
identif
organ
aecopd
bacteria
sputum
virus
npa
serolog
lung
function
clinic
outcom
patient
mortal
nppv
use
length
hospit
stay
assess
mannewhitney
u
test
chisquar
test
fisherexact
test
appropri
data
present
mean
sd
p
valu
consid
signific
altogeth
subject
admit
first
episod
aecopd
concomit
pneumonia
demograph
characterist
patient
shown
tabl
lung
function
result
avail
patient
twelv
patient
die
schedul
appoint
spirometri
wherea
two
refus
return
lung
function
assess
among
subject
lung
function
assess
patient
mild
moder
sever
sever
copd
accord
gold
classif
fortytwo
patient
use
ic
hospit
mean
sd
dose
ic
mcg
beclomethasoneequival
per
day
differ
demograph
characterist
includ
mean
lung
function
valu
subject
ic
addit
stratifi
subject
ic
two
subgroup
high
mcg
beclomethasoneequival
per
day
lowmedium
mcg
beclomethasoneequival
per
day
dose
ic
differ
demograph
data
observ
supplementari
tabl
mean
sd
dose
group
high
dose
lowmedium
dose
ic
mcg
beclomethasoneequival
per
day
respect
among
subject
histori
hypertens
cerebrovascular
accid
diabet
mellitu
ischaem
heart
diseas
congest
heart
failur
malign
respect
patient
manag
gener
medic
ward
none
requir
invas
mechan
ventil
signific
differ
mortal
admiss
mortal
month
nppv
usag
compar
subject
ic
compar
subject
lowmedium
dose
ic
high
dose
ic
supplementari
tabl
clinic
present
subject
summar
tabl
episod
subject
taken
antibiot
within
day
hospit
subject
pneumon
chang
cxr
among
episod
bilater
cxr
chang
wherea
episod
pneumon
chang
involv
lobe
lung
three
subject
develop
pleural
effus
patient
treat
antibiot
therapi
admiss
sputum
blood
cultur
collect
hospit
sputum
cultur
result
shown
tabl
overal
episod
posit
sputum
bacteri
mycobacteri
cultur
respect
two
patient
relat
streptococcu
pneumonia
resist
penicillin
wherea
none
haemophilu
influenza
isol
show
betalactamas
activ
none
one
bacterium
isol
sputum
differ
rate
posit
sputum
bacteri
cultur
group
receiv
antibiot
previou
week
compar
also
differ
rate
posit
influenza
b
virus
use
combin
method
npa
pcr
npa
viral
cultur
blood
serolog
among
subject
receiv
influenza
vaccin
within
month
admiss
compar
without
among
bilater
pneumonia
n
z
microorgan
identifi
h
influenza
influenza
case
pneumon
chang
involv
lobe
bilater
pneumonia
also
bacteria
h
influenza
pneumonia
serratia
sp
virus
identifi
influenza
metapneumoviru
none
subject
bacteri
viral
etiolog
identifi
time
identif
organ
relat
lung
function
subject
shown
tabl
trend
toward
higher
rate
posit
sputum
bacteri
cultur
among
subject
fev
predict
fev
predict
vs
p
z
howev
rate
posit
sputum
bacteri
cultur
differ
among
patient
fev
predict
whose
fev
predict
vs
p
z
similarli
rate
posit
viral
etiolog
statist
differ
copd
subject
differ
diseas
sever
base
lung
function
hospit
length
stay
need
nppv
support
death
rate
admiss
month
readmiss
hospit
month
assess
relat
bacteriolog
virolog
result
tabl
patient
posit
viral
etiolog
higher
chanc
requir
nppv
support
without
viral
identif
either
npa
serolog
vs
p
z
age
sex
presenc
comorbid
medic
ill
diabet
mellitu
hypertens
cerebrovascular
accid
ischaem
heart
diseas
congest
heart
failur
malign
admiss
pneumonia
previou
month
associ
presenc
bacteria
virus
respiratori
specimen
addit
presenc
comorbid
defin
effect
death
rate
length
hospit
stay
compar
subject
without
coexist
medic
ill
best
knowledg
first
prospect
studi
includ
examin
sputum
bacteriolog
viral
multiplex
nestedpcr
assess
respiratori
specimen
patient
admit
medic
ward
aecopd
concomit
pneumonia
infecti
etiolog
could
establish
episod
admiss
rate
posit
sputum
bacteri
cultur
npa
viral
pcr
respect
commonest
bacteria
identifi
pneumonia
p
aeruginosa
h
influenza
wherea
common
virus
involv
influenza
rhinoviru
interestingli
patient
higher
dose
ic
mcg
beclomethasoneequival
per
day
higher
rate
posit
sputum
bacteri
cultur
lower
dose
ic
largest
studi
publish
date
specif
assess
pneumonia
copd
patient
conduct
tabl
identif
organ
relat
lung
function
spain
involv
subject
extens
bacteriolog
test
investig
identifi
infecti
etiolog
case
studi
includ
viral
assess
studi
pneumonia
p
aeruginosa
commonest
bacteria
identifi
contrast
find
torr
et
al
commonest
organ
pneumonia
c
pneumonia
atyp
organ
pneumonia
c
pneumonia
l
pneumophila
detect
serolog
npa
viral
pcr
studi
recent
studi
specif
look
atyp
pathogen
patient
aecopd
without
pneumonia
fail
identifi
organ
sputum
pcr
assess
anoth
studi
involv
patient
admit
pneumon
aecopd
found
infecti
etiolog
bacteri
viral
identifi
patient
use
pair
blood
serolog
test
rate
markedli
higher
find
studi
subject
similar
lung
function
mean
fev
predict
studi
torr
et
al
differ
result
could
explain
basi
lung
function
previou
studi
cap
specif
copd
patient
observ
geograph
differ
bacteri
etiolog
exampl
studi
malaysia
note
higher
preval
gramneg
bacilli
compar
western
countri
uncertain
whether
geograph
factor
could
explain
differ
microbiolog
pattern
variou
studi
recent
use
ic
implic
increas
risk
cap
among
patient
copd
howev
mechan
underli
observ
unclear
increas
pneumonia
appear
repres
increas
number
death
observ
subject
high
dose
ic
higher
rate
posit
sputum
bacteri
cultur
patient
lowmedium
dose
ic
observ
concur
ernst
et
al
adjust
risk
ratio
hospit
pneumonia
greatest
highest
dose
ic
use
mcg
fluticason
equival
dose
per
day
ic
decreas
inflamm
airway
whether
decreas
inflamm
possibl
concomit
decreas
defens
microorgan
could
explain
observ
higher
rate
posit
sputum
cultur
patient
aecopd
concomit
pneumonia
high
dose
ic
higher
rate
pneumonia
copd
patient
ic
certainli
requir
studi
virus
import
caus
agent
cap
among
cap
patient
specif
copd
patient
admit
hospit
chile
respiratori
virus
found
patient
use
viral
immunofluoresc
assay
nasal
swab
serolog
urinari
antigen
commonest
viru
identifi
studi
parainfluenza
virus
sampl
follow
influenza
sampl
contrast
find
influenza
viru
commonest
viru
chosen
viral
pcr
techniqu
main
method
viru
identif
demonstr
previous
pcr
techniqu
time
higher
diagnost
yield
convent
viral
cultur
appear
bacteria
far
common
virus
etiolog
agent
patient
aecopd
concomit
pneumonia
wherea
overlap
viral
bacteria
etiolog
also
low
studi
studi
limit
fact
singl
center
studi
rel
small
sampl
size
addit
lung
function
data
avail
patient
die
schedul
lung
function
appoint
furthermor
npa
pcr
perform
studi
instead
sputum
pcr
sputum
pcr
assess
probabl
would
assess
lower
respiratori
tract
infect
better
use
npa
specimen
previou
studi
use
sputum
nasal
lavag
pcr
shown
diagnost
yield
aecopd
patient
without
pneumonia
higher
induc
sputum
nasal
lavag
comparison
infecti
etiolog
pneumonia
subject
without
copd
avail
collect
clinic
data
respiratori
specimen
subject
pneumonia
without
copd
current
studi
earli
studi
cap
subject
chronic
bronchiti
hong
kong
found
identifi
etiolog
comparison
subject
without
copd
etiolog
appear
differ
pneumonia
mycobacterium
tuberculosi
commonest
organ
summari
infecti
etiolog
could
establish
half
patient
hospit
aecopd
concomit
pneumonia
major
identifi
caus
bacteri
observ
use
higher
dose
ic
associ
higher
rate
posit
sputum
bacteri
cultur
patient
aecopd
concomit
pneumonia
studi
need
investig
copd
patient
ic
appear
prone
pneumonia
report
recent
studi
